Related Articles
Research progress on immunotherapy in triple‑negative breast cancer (Review)
CDK4/6 inhibitor resistance mechanisms and treatment strategies (Review)
Combination therapy with antibody‑drug conjugate RC48 (disitamab vedotin) and zimberelimab (PD‑1 inhibitor) successfully controlled recurrent HER2‑positive breast cancer resistant to trastuzumab emtansine: A case report
HER2<sup>+</sup> advanced gastric cancer: Current state and opportunities (Review)
Targeted therapy in HER2‑positive breast cancer (Review)